It was an afternoon of high drama as BioEscalator tenants took to the floor in our recent annual Pitch Battle to compete for the Best Pitch prize, sponsored by Oxford North, and a range of other accolades.
U-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
Who knew? Young adults do listen to their parents, and the BioEscalator is very glad about that. Becson Ody, our first Business Administration & Reception apprentice, found out about apprenticeships through his father, who is a \u2018big advocate\u2019.
JLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
The BioEscalator is very proud to be home to a stellar collection of companies using cutting-edge science to tackle profound medical challenges. Our new Portfolio 2025 brings them together to showcase their innovative approaches and provide a valuable guide for potential investors and partners.
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Summer 2025 edition of the BioEscalator Bulletin.
PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology\r\ncompany harnessing the power of non-coding human genetics to discover first-in-class antibody\r\ntreatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business\r\nOfficer with immediate effect.
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.
Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab\u2019s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
U\u2011Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women\u2019s health by providing funding, expert mentorship, and access to Merck\u2019s global network of scientific and clinical leaders.
Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.
Orfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit \u2013 and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown from two to seven employees, raised an Oxford Science Enterprises-backed seed round and started to understand where its approach might have the greatest clinical impact. Now it\u2019s raising additional funding.
Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company\u2019s lead \u2018off-the-shelf\u2019 cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company\u2019s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).
Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.
Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.
![\"Dr](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/an-insight-into-our-sixth-annual-pitch-battle-2013-with-competition-is-as-intense-as-ever/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n